modulators, receptor internalization, and navigating the transition from academic GPCR research to biotech She now works at Gator Bio, where she transitioned from Field Application Scientist - serving as a technical constraint on pharmacological interpretation Equilibrium vs. dynamic frameworks for studying receptor biology An assay measures a specific thing - not the biology you assume it measures One of Livingston's most Kathryn E Livingston is currently a Product Manager at Gator Bio , a biotechnology company providing

Intended for GPCR scientists, cell biologists, and drug discovery professionals working on receptor signaling Instructor Bio Davide Calebiro's work has reshaped how the field understands where and when GPCRs signal

Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr.

Not OK to use: Advertising Spam Anything misleading or annoying Social media bios Paying or offering

You’ll be asked for: Instructor info – name, email, affiliation, short bio, photo, and optional social

<< Back to podcast list Strategic Partner(s) Translating computational approaches to GPCR biologists Riccardo Capelli is an assistant professor in Applied Physics at the Department of Biosciences, University methods such as structure-based models and enhanced sampling techniques, as well as their application to biomolecular ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural Biology

to podcast list Strategic Partner(s) Custom Molecules, Fluorescent Probes: When Chemists Think Like Biologists CSO of Celtarys Research, shares the story behind the company’s journey from academic curiosity to biotech When the time came to decide whether to leave the lab and lead Celtarys into biotech, she took the leap That changed with support from Galicia’s robust biotech network, and the company quickly defined its It’s about enabling biology.” — Maria Majellaro Through its partnership with Dr.

This conversation covers thermostabilization, cryoEM, and GPCR structural biology. << Back to podcast list Strategic Partner(s) Chris Tate: Thermostabilizing GPCRs for Structural Biology For most of the 1990s and early 2000s, GPCR structural biology was not a biology problem - it was a stability problem ABOUT THE GUEST Chris Tate is a group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, where his research focuses on the structural and biochemical study of membrane proteins, with particular

Transform your biotech idea or data into a clear, strategic roadmap with aligned biology, timelines, Home About Services News Get in Touch Welcome Biotech Growth Wherever You Are in Discovery—Let’s Build a Plan That Moves You Forward Align your biology, timeline and CRO roadmap. Biotech teams often tell me: “We have too many CROs and not enough clarity.” We'll define what matters, when to decide, and how to act—based on your biology, not just what's easy

Joseph Kim exploring GPCR structural biology, cryo-electron microscopy, opioid receptor pharmacology, like the galanin receptor family. << Back to podcast list Strategic Partner(s) Joseph Kim: Structural Biology Joseph Kim discusses the intersection of structural biology, membrane protein biochemistry, and drug Joseph Kim is a structural biologist studying membrane proteins and GPCR pharmacology. His work combines structural biology, membrane protein biochemistry, and pharmacological insights to

GPCR — Scaling Biotech Beyond the Bench Turning scientific excellence into scalable organizations. Leadership 👉 Ambition is the default setting of biotech. This is the hidden cost of ambition in biotech leadership. Not failure. Not poo Attila Foris Mar 2 The Real Cost of Strategic Overload in Biotech 👉 In early-stage biotech, At the same time, the team is preparing for biotech fundraising.

logistics at GeneTex International in Taiwan, which she joined in 2016 after completing a PhD in stem cell biology 05:49 The antibody reproducibility crisis and how GeneTex responded 09:25 Lin's path from stem cell biology

journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology , exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology trajectory, discoveries, and how their research contributed to the shared pool of knowledge about GPCR biology

Advanced GPCR webinars for pharmacologists and biotech scientists. Live Q&A. Terry Kenakin - UNC Chappel Hill | Terry's Pharmacology Corner Topics Covered The biological basis of GPCR webinars are free, live online scientific sessions focused on G protein-coupled receptor biology Every session is grounded in receptor biology with a focus on what's practical and applicable. A working understanding of GPCR biology helps you get the most from each session.

testing, and backed by thousands of peer-reviewed publications and partnerships with leading pharma and biotech pharmaco-chaperone discovery Flexible formats: cell line assay kits, ready-to-use eXpress kits, qualified bioassays intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech Expert-led webinars and masterclasses with leading researchers Structured networking for scientists and biotech

curated intelligence briefings with expert analysis Community access — connect with scientists and biotech

Researchers, biotech professionals, CRO teams, students, and anyone seeking deeper insights, networking

GPCR Masterclass is a live scientific discussion with a leading expert in GPCR pharmacology, receptor biology designed for GPCR researchers, pharmacologists, and drug discovery scientists working in academia, biotech

talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech

Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology

After spending two years at the Cleveland Institute of Art, he earned degrees in Biochemistry and Chemistry He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs Miller School of Medicine in 2016, where he is currently a practicing molecular pharmacologist and biophysicist , systems and synthetic biologist, technologist, heavy CRISPR user, protein sequence- and structure-based

His lab combines classical pharmacology with cancer genomics, bioinformatics, and synthetic lethality uveal melanoma, GαS mutations across pancreatic, colon, and appendix cancers, and chemokine receptor biology and the druggable FAK node CXCR3 and the chemokine axis that gates immunotherapy response Structural biology produced transforming efficiencies comparable to Ras, and the community largely looked away because the biology from Europe, high-throughput screens from Japan, and biology from UCSD.

underappreciated axis of pharmacological modulation, and long-running collaborations on beta-adrenergic receptor biology

A reagent gap that holds back the biology GPCR activity is targeted by one-third of all FDA-approved Part of the gap is biology. Multipass transmembrane proteins are genuinely difficult targets.

biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology & Toxicology’, and in 2021 also named him a Highly Cited Researcher in the additional category of ‘Biology & Biochemistry’. They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before She received her undergraduate degree in Biotechnology from KIIT University in India. Monserrat Avila Zozaya I did a PhD in cell biology at CINVESTAV, Mexico. About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery Biology his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical and biotech

Gloriam on orphan GPCR biology, GPCRDB, biased signaling, and how the data analysis bottleneck is reshaping This conversation explores the intersection of computational biology, cheminformatics, and structural research group working across data science, computational drug design, pharmacology, and structural biology His primary research focus is orphan GPCR biology, with particular emphasis on identifying endogenous for experimentalists, but as the primary constraint to overcome in advancing receptor biology.

Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry During his last year of studies, Timo performed research in the biopharmaceutical company Argen X and

Duvall emphasizes the value of model systems and cross-species discoveries in GPCR biology. considering novel ways to connect molecular pharmacology with organismal phenotype, especially in vector biology About Laura Duvall Laura Duvall trained in biochemistry and behavioral biology at the University of Pennsylvania Duvall established her laboratory at Columbia University, where she is part of the Department of Biological Her research is consistently motivated by uncovering new biological connections that can bridge basic

He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr.